Table 6 Clinical Characteristics of SARS-CoV-2-Infected Patients Who Received Convalescent Plasma
From: Potential Drugs and Remedies for the Treatment of COVID-19: a Critical Review
| Â | Patient | ||||
|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | |
Sex | Male | Male | Female | Female | Male |
Age, y | 70s | 60s | 50s | 30s | 60s |
Weight, kg | 55 | 85 | 60 | 41.5 | 87 |
Smoking | No | No | No | No | No |
Blood type | B | B | B | A | B |
Coexisting chronic disease | None | Hypertension; mitral Insufficiency | None | None | None |
Disease presentation and course | |||||
 Estimated incubation period, da | 1 | 7 | 3 | 7 | 15 |
 Interval between symptom onset and admission, d | 2 | 4 | 2 | 2 | 3 |
 Interval between admission and plasma transfusion, d | 22 | 10 | 20 | 19 | 20 |
 Complications prior to plasma transfusion | Bacterial pneumonia; Severe ARDS; MODS | Bacterial pneumonia; Fungal pneumonia; severe ARDS; myocardial damage | severe ARDS | severe ARDS | severe ARDS |
 Most severe disease classification | Critical | Critical | Critical | Critical | Critical |
Treatments | |||||
 Steroids | Methylprednisolone | Methylprednisolone | Methylprednisolone | Methylprednisolone | Methylprednisolone |
 Antivirals | Lopinavir/ritonavir; Interferon alfa-1b; favipiravir | Lopinavir/ritonavir; Arbidol; darunavir | Lopinavir/ritonavir; Interferon alfa-1b | Interferon alfa-1b; favipiravir | Lopinavir/ritonavir; Interferon alfa-1b |